<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01798095</url>
  </required_header>
  <id_info>
    <org_study_id>JHP-03</org_study_id>
    <nct_id>NCT01798095</nct_id>
  </id_info>
  <brief_title>Equivalence Study of Specificity of PPD</brief_title>
  <acronym>03</acronym>
  <official_title>A Randomized, Double-blind, Equivalence Study of the Specificity of Tuberculin Purified Protein Derivative (PPD) (Aplisol®) in Comparison With a Reference Standard</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JHP Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>JHP Pharmaceuticals LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine if investigational products and reference standard produce similar responses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary:&#xD;
&#xD;
      To determine if the 2 investigational products (Aplisol formulated from the new Tuberculin&#xD;
      PPD drug substance and the reference standard PPD-S2) produce qualitatively similar responses&#xD;
      (positive or negative) in subjects who are uninfected with M. tuberculosis (Mtb) or other&#xD;
      mycobacteria.&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
        1. To determine if the 2 investigational products have equivalent specificity for detecting&#xD;
           subjects currently or previously infected with Mtb;&#xD;
&#xD;
        2. To assess the tolerability of the investigational products in terms of the local and&#xD;
           systemic reactogenicity events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of similarity in responses</measure>
    <time_frame>72 hours</time_frame>
    <description>To determine if the 2 investigational products (Aplisol formulated from the new Tuberculin PPD drug substance and the reference standard PPD-S2) produce qualitatively similar responses (positive or negative) in subjects who are uninfected with M. tuberculosis (Mtb) or other mycobacteria.Skin test responses will be used to determine product similarity in responses.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine equivalent specificity</measure>
    <time_frame>72 hours</time_frame>
    <description>To determine if the 2 investigational products have equivalent specificity for detecting subjects currently or previously infected with Mtb; 2) To assess the tolerability of the investigational products in terms of the localand systemic reactogenicity events. Skin responses to new PPD and reference standard will be monitored to determine equivalent specificity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Tuberculosis Infection</condition>
  <arm_group>
    <arm_group_label>Aplisol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To confirm the response of PPD materials</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPD Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Determine equivalent specificity for new material compared to standard material.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aplisol@ PPD material</intervention_name>
    <description>Determine equivalency of materials</description>
    <arm_group_label>Aplisol</arm_group_label>
    <arm_group_label>PPD Standard</arm_group_label>
    <other_name>Aplisol@</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Reference Standard</intervention_name>
    <description>Reference standard material for comparison to newly produced materials.</description>
    <arm_group_label>Aplisol</arm_group_label>
    <arm_group_label>PPD Standard</arm_group_label>
    <other_name>US Reference Standard</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or nonpregnant females, age 18 to 70 years&#xD;
&#xD;
               -  Negligible risk of manifesting a positive PPD test as evidenced by:&#xD;
&#xD;
                    -  Prior history of negative PPD test or interferon gamma release assay (IGRA)&#xD;
                       within 14 months before Screening&#xD;
&#xD;
                    -  No history of Bacillus Calmette- Guérin vaccination; or if vaccination&#xD;
                       status is uncertain, was born in the US and did not live outside the US as a&#xD;
                       child&#xD;
&#xD;
                    -  No history of Mtb or Mtb therapy (including isoniazid, rifampin, ethambutol,&#xD;
                       pyrazinamide, or streptomycin)&#xD;
&#xD;
                    -  No history of infection with atypical mycobacteria, including suspicious&#xD;
                       chest roentgenogram&#xD;
&#xD;
                    -  No history of high risk medical conditions (eg, HIV infection or other&#xD;
                       immunosuppressive conditions, severe chronic renal disease [as evidenced by&#xD;
                       a creatinine clearance &lt; 30 ml/min], poorly controlled diabetes mellitus,&#xD;
                       silicosis, intravenous drug use, or alcohol abuse)&#xD;
&#xD;
                    -  No known close contact to a confirmed Mtb case (family or social setting)&#xD;
&#xD;
                    -  No history of living or travelling in India, China, Sub-Saharan Africa, or&#xD;
                       Southeast Asia in the past 6 months&#xD;
&#xD;
                    -  No exposure (other than casual) to high-risk environments for Mtb exposure&#xD;
                       (eg, prisons, homeless shelters); healthcare workers are allowed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is of childbearing potential and unable to use contraceptives; is planning&#xD;
             pregnancy; is pregnant or lactating&#xD;
&#xD;
               -  History of anaphylactic type reaction or other severe reaction to PPD in the&#xD;
                  past, including a history of blistering or sloughing&#xD;
&#xD;
               -  Presence of conditions that may suppress TST reactivity, including:&#xD;
&#xD;
        Protocol No. JHP-Aplisol-03 Confidential 04 May 2012 Page 8 of 38&#xD;
&#xD;
          -  Acute viral infections, including measles, mumps, chicken pox, human immunodeficiency&#xD;
             virus (HIV1, HIV2). Mild viral syndromes are allowed.&#xD;
&#xD;
          -  Acute bacterial infections including typhoid fever, brucellosis, typhus, leprosy, or&#xD;
             pertussis&#xD;
&#xD;
          -  Acute systemic fungal infection&#xD;
&#xD;
          -  Live virus vaccinations within the past 6 weeks, including measles, mumps, polio,&#xD;
             varicella, or FluMist®&#xD;
&#xD;
          -  Metabolic derangements (eg, poorly controlled diabetes, Cushing syndrome, chronic&#xD;
             renal failure [as evidenced by a creatinine clearance &lt; 30 ml/min])&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Arlene Lund, B.Sc.</last_name>
    <phone>919-985-3220</phone>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Joe Santor, Pharm. D.</last_name>
      <phone>903-877-7632</phone>
      <email>clin.res@uthct.edu</email>
    </contact>
    <investigator>
      <last_name>David Griffith, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>January 31, 2013</study_first_submitted>
  <study_first_submitted_qc>February 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2013</study_first_posted>
  <last_update_submitted>February 21, 2013</last_update_submitted>
  <last_update_submitted_qc>February 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TB, Aplisol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

